Production Of A Highly Concentrated Monoclonal Antibody
Source: Cytiva
By Sandeep Kristiansson
The subcutaneous (SC) delivery of monoclonal antibodies (mAbs) offers advantages over intravenous (IV) infusion, for it is less invasive, reduces administration time, and enables self-administration. However, to meet the required dosage within the limited volume of SC administration, formulations often need to be highly concentrated. Often, formulations exceed 100 g/L and have the potential to reach over 200 g/L. Discover how you can achieve a final mAb concentration above 200 g/L while maintaining critical quality attributes.
access the Application Note!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.
Subscribe to Biosimilar Development
X
Subscribe to Biosimilar Development
Cytiva
This website uses cookies to ensure you get the best experience on our website. Learn more